Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-27T04:01:35.687Z Has data issue: false hasContentIssue false
  • English
  • Français

Palivizumab compliance in congenital heart disease patients: factors related to compliance and altered lower respiratory tract infection viruses after palivizumab prophylaxis

Published online by Cambridge University Press:  19 May 2020

Kutay Sel Open the ORCID record for Kutay Sel [Opens in a new window] ,
Ebru Aypar Open the ORCID record for Ebru Aypar [Opens in a new window] ,
Yasemin Nuran Dönmez ,
Emil Aliyev ,
Hakan Hayrettin Aykan Open the ORCID record for Hakan Hayrettin Aykan [Opens in a new window] ,
Tevfik Karagöz  and
Dursun Alehan
Kutay Sel*
Affiliation:
Department of Pediatric Cardiology, Ihsan Doğramacı Children’s Hospital, Hacettepe University Faculty of Medicine, Ankara, Turkey
Ebru Aypar
Affiliation:
Department of Pediatric Cardiology, Ihsan Doğramacı Children’s Hospital, Hacettepe University Faculty of Medicine, Ankara, Turkey
Yasemin Nuran Dönmez
Affiliation:
Department of Pediatric Cardiology, Ihsan Doğramacı Children’s Hospital, Hacettepe University Faculty of Medicine, Ankara, Turkey
Emil Aliyev
Affiliation:
Department of Pediatric Cardiology, Ihsan Doğramacı Children’s Hospital, Hacettepe University Faculty of Medicine, Ankara, Turkey
Hakan Hayrettin Aykan
Affiliation:
Department of Pediatric Cardiology, Ihsan Doğramacı Children’s Hospital, Hacettepe University Faculty of Medicine, Ankara, Turkey
Tevfik Karagöz
Affiliation:
Department of Pediatric Cardiology, Ihsan Doğramacı Children’s Hospital, Hacettepe University Faculty of Medicine, Ankara, Turkey
Dursun Alehan
Affiliation:
Department of Pediatric Cardiology, Ihsan Doğramacı Children’s Hospital, Hacettepe University Faculty of Medicine, Ankara, Turkey
*
Author for correspondence: Kutay Sel, Department of Pediatric Cardiology, Hacettepe University Faculty of Medicine, Ihsan Doğramacı Childrens Hospital, 06100, Samanpazari, Ankara, Turkey. Tel: +90 312 3051157; Fax: +90 312 3090220; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Lower respiratory tract infections caused by respiratory syncytial virus can be severe during infancy, which requires admission to the hospital. These infections may be more severe especially in patients with congenital heart disease. Passive immunisation with palivizumab, a monoclonal antibody, is recommended in high-risk infants. We tried to determine the compliance rates, factors affecting compliance, and also other microorganisms responsible for lower respiratory tract infections after palivizumab prophylaxis in these patients.

Methods:

We evaluated patients’ compliance to prophylaxis with palivizumab in two consecutive respiratory syncytial virus seasons from pharmacy records. We also investigated factors affecting compliance and the frequency of hospitalisations for lower respiratory tract infections. We investigated the causative microorganisms detected in hospitalised patients.

Results:

In this study, 86.7% of the desired number of injections was achieved in 176 patients in two seasons. Out of these, 117 patients (66.4%) received all the doses they were prescribed. Although not statistically significant, compliance to prophylaxis was higher in male patients, cyanotic patients, those who started under 1 year old, and who lived in the city centre. Human metapneumovirus, parainfluenza type 3, and bocavirus were detected in the hospitalised patients.

Conclusion:

Patients with congenital heart disease can survive the period of infancy with less problem by making palivizumab prophylaxis more effective, and awareness about non- respiratory syncytial virus factors may be a guide for the development of new treatments.

Keywords

Congenital heart diseaserespiratory syncytial viruspalivizumab
Type
Original Article
Information
Cardiology in the Young , Volume 30 , Issue 6 , June 2020 , pp. 818 - 821
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Simoes, EAF.Respiratory syncytial virus infection. Lancet. 1999 Sep 4;354(9181):847–52.CrossRefGoogle ScholarPubMed
Drysdale, SB, Green, CA, Sande, CJ. Best practice in the prevention and management of paediatric respiratory syncytial virus infection. Ther Adv Infect Dis. 2016;3(2):63–71Google ScholarPubMed
Feltes, TF, Cabalka, AK, Meissner, HC, et al.Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–40.CrossRefGoogle Scholar
Thorburn, K.Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child. 2009;94:99–103.CrossRefGoogle ScholarPubMed
American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415–420.CrossRefGoogle Scholar
Schanzer, DL, Langley, JM, Tam, TW.Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J. 2006;25:795–800.CrossRefGoogle ScholarPubMed
Glezen, WP, Taber, LH, Frank, AL, Kasel, JA.Risk of primary infection and reinfection with respiratory syncytial virus Am J Dis Child. 1986;140:543–546.Google ScholarPubMed
Committee on Infectious Diseases; American Academy of Pediatrics; Kimberlin, DW, Brady, MT, Jackson, MA, Long, SS. Section 3: Summaries of Infectious Diseases, in Red Book; 2018.Google Scholar
Resch, B, Michel-Behnke, I.Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab. Curr Opin Cardiol. 2013;28:85–91.CrossRefGoogle ScholarPubMed
Chang, RKR, Chen, AY.Impact of palivizumab on RESPİRATORY SYNCYTİAL VİRUS hospitalizations for children with hemodynamically significant congenital heart disease. Pediatr Cardiol. 2010;31(1):90–5.CrossRefGoogle ScholarPubMed
Ozyurt, A, Narin, N, Baykan, A, et al.Efficacy of palivizumab prophylaxis among Infants with congenital heart disease: a case control study. Pediatr Pulm. 2015;50:1025–32.CrossRefGoogle ScholarPubMed
Kanra, G, Tezcan, S, Yılmaz, G.Turkish national respiratory syncytial virus team respiratory syncytial virus epidemiology in Turkey. Turk J Pediatr. 2005;47:303–08.Google ScholarPubMed
Yurdakök, M.Türkiye’de respiratuvar sinsityal virus enfeksiyonlarının mevsimsel özellikleri: iki yıllık epidemiyolojik calışma. Çocuk Sağlığı ve Hastalıkları Dergisi. 2012;55:1–8.Google Scholar
Synagis (palivizumab). Full prescribing information. Gaithersburg, MD: MedImmune, LLC; 2008.. Available at: http://www.medimmune.com/pdf/products/synagis_pi.pdf.Google Scholar
Frogel, MP, Stewart, DL, Hoopes, M, Fernandes, AW, Mahadevia, PJ.A systematic review of compliance with palivizumab administration for respiratory syncytial virus immunoprophylaxis. J Manag Care Pharm. 2010:Jan–Feb;16(1):46–58.Google Scholar
Chan, P, Li, A, Paes, B, Abraha, H, Mitchell, I, Lanctôt, KL, CARESS investigators. Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian registry of palivizumab. Pediatr Infect Dis J. 2015 Dec;34(12):e290–7.CrossRefGoogle ScholarPubMed